CAMP4 Therapeutics (NASDAQ:CAMP) Stock Crosses Above 50-Day Moving Average on Disappointing Earnings

Key Points

• Shares rose 9.1% to $4.06, moving above the 50-day moving average of $3.84.
• CAMP4 reported a quarterly loss of $0.37 per share, wider than the $0.20 loss analysts expected; revenue was $1.90 million.
• Analysts give the stock a consensus “Moderate Buy” rating and a $10.44 average price target, though recent insider trading included sales totaling 593,613 shares over 90 days.

CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) shares crossed above its 50 day moving average during trading on Friday following a better than expected earnings announcement. The stock has a 50 day moving average of $3.84 and traded as high as $4.06. CAMP4 Therapeutics shares last traded at $4.06, with a volume of 128,677 shares traded.

The Wireless communications provider reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.17). The firm had revenue of $1.90 million for the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%.

Analyst Ratings Changes

A number of research firms have recently weighed in on CAMP. Raymond James Financial started coverage on shares of CAMP4 Therapeutics in a research report on Friday, October 23rd. They issued a "strong-buy" rating and a $10.00 price target for the company. UBS Group set a $15.00 price objective on shares of CAMP4 Therapeutics in a research report on Friday, August 14th. Needham & Company LLC began coverage on shares of CAMP4 Therapeutics in a report on Thursday, October 15th. They issued a "buy" rating and a $8.00 target price on the stock. Chardan Capital decreased their price objective on shares of CAMP4 Therapeutics from $6.50 to $6.00 and set a "buy" rating on the stock in a research note on Tuesday, September 29th. Finally, Wall Street Zen lowered CAMP4 Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, October 10th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $10.44.

Insider Activity

In other CAMP4 Therapeutics news, CFO Kelly Gold purchased 10,000 shares of the stock in a transaction dated Monday, August 31st. The shares were bought at an average price of $3.96 per share, with a total value of $39,600.00. Following the completion of the transaction, the chief financial officer directly owned 10,000 shares in the company, valued at approximately $39,600. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Andrew Schwab sold 400,000 shares of the company's stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $4.04, for a total transaction of $1,616,000.00. Following the sale, the director directly owned 2,033,270 shares in the company, valued at $8,214,410.80. This trade represents a 16.44% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 593,613 shares of company stock valued at $2,504,037. 21.69% of the stock is owned by company insiders.

Institutional Trading of CAMP4 Therapeutics

Hedge funds have recently made changes to their positions in the stock. Jupiter Topco LLC bought a new stake in shares of CAMP4 Therapeutics during the 2nd quarter valued at $27,581,000. 5AM Venture Management LLC purchased a new position in CAMP4 Therapeutics during the second quarter valued at $25,647,928. Trails Edge Capital Partners LP bought a new position in shares of CAMP4 Therapeutics during the 2nd quarter valued at approximately $8,446,935. BlackRock Inc. bought a new position in shares of CAMP4 Therapeutics during the 2nd quarter valued at approximately $7,185,000. Finally, SummitTX Capital L.P. purchased a new stake in CAMP4 Therapeutics in the 1st quarter worth approximately $1,497,000.

CAMP4 Therapeutics Trading Up 9.1%

The company has a market cap of $254.76 million, a P/E ratio of -1.90 and a beta of 0.28. The business's 50 day simple moving average is $3.84 and its 200 day simple moving average is $4.20.

About CAMP4 Therapeutics

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing medicines that increase the production of disease-relevant proteins by activating the expression of specific genes. The company's approach is designed to address diseases caused by insufficient protein levels, including certain genetic disorders in which boosting activity from a functional gene copy may provide therapeutic benefit.

CAMP4 uses its Regulatory Action Platform, or RAP, to identify regulatory elements that control RNA production and discover small-molecule compounds capable of increasing the expression of selected genes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.